According to Rhรถn-Klinikum's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 25.7544. At the end of 2024 the company had a P/E ratio of 21.4.
Year | P/E ratio | Change |
---|---|---|
2024 | 21.4 | 24.03% |
2023 | 17.2 | -57.18% |
2022 | 40.3 | 17.6% |
2021 | 34.2 | -95.85% |
2020 | 825 | 2967.79% |
2019 | 26.9 | -11.17% |
2018 | 30.3 | -46.3% |
2017 | 56.4 | 84.56% |
2016 | 30.5 | 31.33% |
2015 | 23.3 | 838.64% |
2014 | 2.48 | -92.65% |
2013 | 33.7 | 41.07% |
2012 | 23.9 | 83.59% |
2011 | 13.0 | -20.12% |
2010 | 16.3 | 1.92% |
2009 | 16.0 | 9.45% |
2008 | 14.6 | -29.93% |
2007 | 20.9 | 137.07% |
2006 | 8.80 | 82.16% |
2005 | 4.83 | 29.6% |
2004 | 3.73 | -5.51% |
2003 | 3.95 | 32.35% |
2002 | 2.98 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.